Oncologic Management of Hereditary Colorectal Cancer

di Yacoub, George, Nagalla, Srikanth, Aklilu, Mebea
Pubblicazione 2012

Paraneoplastic Leukocytosis and Thrombocytosis as Prognostic Biomarkers in Non-small Cell Lung Cancer

di BODDU, Prajwal, VILLLINES, Dana, AKLILU, Mebea
Pubblicato in Zhongguo Fei Ai Za Zhi (2016)

Adjuvant Chemotherapy is Associated with Improved Survival in Patients with Stage II Colon Cancer

di Casadaban, Leigh, Rauscher, Garth, Aklilu, Mebea, Villenes, Dana, Freels, Sally, Maker, Ajay V.
Pubblicato in Cancer (2016)

Reverse translation of phase I biomarker findings links the activity of angiotensin-(1–7) to repression of hypoxia inducible factor-1α in vascular sarcomas

di Petty, W Jeffrey, Aklilu, Mebea, Varela, Victor A, Lovato, James, Savage, Paul D, Miller, Antonius A
Pubblicazione 2012

Phase II Trial of Adjuvant Oral Thalidomide Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Disease from Colorectal/Appendiceal...

di Shen, Perry, Thomas, Christopher R., Fenstermaker, Joyce, Aklilu, Mebea, McCoy, Thomas P., Levine, Edward A.
Pubblicazione 2014

A brief yoga intervention implemented during chemotherapy: A randomized controlled pilot study

di Sohl, Stephanie J., Danhauer, Suzanne C., Birdee, Gurjeet S., Nicklas, Barbara J., Yacoub, George, Aklilu, Mebea, Avis, Nancy E.
Pubblicato in Complement Ther Med (2016)

Optimal Timing of Systemic Therapy in Resectable Colorectal Liver Metastases

di IHEMELANDU, CHUKWUEMEKA, LEVINE, EDWARD A., AKLILU, MEBEA, YACOUB, GEORGE, HOWERTON, RUSSELL, BOLEMON, BRITT, GRAHAM, MATTHEW, RUSSELL, GREG, SHEN, PERRY
Pubblicazione 2013

Outcomes of Patients With Esophageal Cancer Staged With [(18)F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET): Can Postchemoradiotherapy FDG-PET Predict the Utility of R...

di Monjazeb, Arta Monir, Riedlinger, Greg, Aklilu, Mebea, Geisinger, Kim R., Mishra, Girish, Isom, Scott, Clark, Paige, Levine, Edward A., Blackstock, A. William
Pubblicazione 2010

A two-cohort phase 1 study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine and erlotinib during radiotherapy for unresectable pancreatic carcinoma

di Raftery, Laura, Tepper, Joel E, Goldberg, Richard M., Blackstock, A. William, Aklilu, Mebea, Bernard, Stephen A., Ivanova, Anastasia, Davies, Janine M., O’Neil, Bert H.
Pubblicazione 2013

A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

di Geynisman, Daniel M, Zha, Yuanyuan, Kunnavakkam, Rangesh, Aklilu, Mebea, Catenacci, Daniel VT, Polite, Blase N, Rosenbaum, Cara, Namakydoust, Azadeh, Karrison, Theodore, Gajewski, Thomas F, Kindler, Hedy L
Pubblicazione 2013

A Phase II study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer

di WONG, NAN SOON, FERNANDO, NISHAN H., NIXON, ANDREW B., CUSHMAN, STEPHANIE, AKLILU, MEBEA, BENDELL, JOHANNA C., MORSE, MICHAEL A., BLOBE, GERARD C., ASHTON, JILL, PANG, HERBERT, HURWITZ, HERBERT I.
Pubblicazione 2011

The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery

di Cochran, D. Clay, Chan, Michael D., Aklilu, Mebea, Lovato, James F., Alphonse, Natalie K., Bourland, J. Daniel, Urbanic, James J., McMullen, Kevin P., Shaw, Edward G., Tatter, Stephen B., Ellis, Thomas L.
Pubblicazione 2012

A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastati...

di Morse, Michael A., Niedzwiecki, Donna, Marshall, John L., Garrett, Christopher, Chang, David Z., Aklilu, Mebea, Crocenzi, Todd S., Cole, David J., Dessureault, Sophie, Hobeika, Amy C., Osada, Takuya, Onaitis, Mark, Clary, Bryan M., Hsu, David, Devi, Gayathri R., Bulusu, Anuradha, Annechiarico, Robert P., Chadaram, Vijaya, Clay, Timothy M., Lyerly, H. Kim
Pubblicazione 2013